A5102782419- Inflammatory Bowel Disease
- Tuberculosis Research and Epidemiology
- Diagnosis and treatment of tuberculosis
- Microscopic Colitis
- Biosimilars and Bioanalytical Methods
- Mycobacterium research and diagnosis
- Pharmaceutical studies and practices
- Immunodeficiency and Autoimmune Disorders
- Esophageal and GI Pathology
- COVID-19 Clinical Research Studies
- Diverticular Disease and Complications
- Eosinophilic Esophagitis
- SARS-CoV-2 and COVID-19 Research
- Gastrointestinal motility and disorders
- Anorectal Disease Treatments and Outcomes
- COVID-19 and healthcare impacts
- Pharmaceutical Economics and Policy
- Gastroesophageal reflux and treatments
Universidade de São Paulo
2021-2023
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2019-2022
Therapeutic drug monitoring (TDM) during induction therapy with anti-tumor necrosis factor drugs has emerged as a strategy to optimize response these biologics and avoid undesired outcomes related inadequate exposure. This study aimed describe clinical, biological, endoscopic remission rates at six months in Brazilian inflammatory bowel disease (IBD) patients following proactive TDM algorithm guided by IFX trough levels (ITL) antibodies (ATI) induction, week six. A total of 111 IBD were...
In this analysis we aimed to describe Brazilian inflammatory bowel disease (IBD) patients' knowledge and perceptions regarding biosimilars compare with viewpoints from non-Brazilian patients.An online survey consisting of 19 questions was made available by the European Federation Crohn's Ulcerative Colitis Associations between July 2018 December 2018. Only respondents who had heard were asked respond all questions.A total 102 IBD patients responded survey. The majority (78.4%) been exposed...
Anti-tumor necrosis factor (anti-TNF) drugs have been the mainstay therapy for moderate to severe inflammatory bowel disease (IBD) over past 25 years. Nevertheless, these are associated with serious opportunistic infections like tuberculosis (TB). Brazil is ranked among 30 countries highest incidence of TB in world. This study aimed at identifying risk factors development active and describing clinical characteristics outcomes IBD patients followed a tertiary referral center Brazil.We...
<b><i>Introduction:</i></b> The coronavirus disease 2019 (COVID-19) pandemic has increased concern regarding SARS-CoV-2 infection in inflammatory bowel (IBD) patients, especially those on immunosuppressive therapies or with active disease. There are limited reports describing the clinical features of COVID-19 an IBD population, and impact immunosuppression severity remains unclear. <b><i>Case Report:</i></b> A 33-year-old female patient a long...
BACKGROUND: Despite the decline in incidence of Tuberculosis (TB) worldwide, this disease still causes high rates morbimortality. It is estimated that TB caused 1.3 million deaths worldwide 2017. Brazil an endemic country and it counts nearly 70,000 new cases per year (1). Whether risk infection Inflammatory Bowel Disease (IBD) patients related to immunosuppressants or itself controversial. This study aimed evaluate active with IBD, its relationship immunosuppressive treatment a tertiary...
Abstract: Perianal fistulizing Crohn’s disease (PFCD) is a disabling complication of dis-ease (CD) that can significantly impact the patients’ quality life (QoL) and often requires multi-disciplinary care. Clinical trials assessing efficacy medical surgical interventions for fis-tulas usually evaluate outcomes such as closure fistula tracts or radiologic healing. However, these traditional outcome assessments fail to capture from per-spectives. In this context, regulatory authorities have...
O acometimento esofágico por doenças autoimunes tem sido cada vez mais reportado na literatura. A incidência e a prevalência de esofagite eosinofílica têm aumentado nas últimas décadas as opções terapêuticas evoluído bastante, mas o corticoide tópico uso inibidores bombas prótons permanecem como excelentes terapêuticas. Diversas sistêmicas podem cursar com secundário, prejuízos da motilidade do corpo esfíncter esofagiano inferior. Esse se traduz principalmente em disfagia refluxo...
Abstract Background Patients with inflammatory bowel diseases (IBD) have a greater risk of developing opportunistic infections, especially if they are under immunosuppressants and biological agents. Anti-tumor necrosis factor alpha (anti-TNF) has considerably increased the tuberculosis (TB) in IBD patients. Brazil is considered an endemic area for TB safety anti-TNF agents patients previous diagnosed infection remains to be elucidated. The aim this study was evaluate anti-TNFs at tertiary...